<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="respiratory disease, and dissemination in immunocompromised individuals. HAdV causes lytic" exact="infection" post="of the mucoepithelial cells of the conjunctiva and cornea,"/>
 <result pre="cells of the conjunctiva and cornea, as well as latent" exact="infection" post="of lymphoid and adenoid cells. Epidemic keratoconjunctivitis (EKC) is"/>
 <result pre="handle the challenges associated with viral persistence and dissemination. Several" exact="treatment" post="modalities have been investigated, both systemically and locally, to"/>
 <result pre="not only mitigate symptoms but reduce the course of the" exact="infection" post="and prevent the risk of long-term complications. These options"/>
 <result pre="outcomes and were well tolerated in clinical trials for the" exact="treatment" post="of EKC. Possible, future treatment considerations include sialic acid"/>
 <result pre="in clinical trials for the treatment of EKC. Possible, future" exact="treatment" post="considerations include sialic acid analogs, cold atmospheric plasma, N-chlorotaurine,"/>
 <result pre="plasma, N-chlorotaurine, and benzalkonium chloride. Continued investigation and evaluation of" exact="treatment" post="are warranted to reduce the economic burden and potential"/>
 <result pre="Introduction Human adenovirus (HAdV) is the most common cause of" exact="infection" post="to the ocular surface, accounting for up to 75%"/>
 <result pre="heavy economic burden and necessitate the establishment of a standard" exact="treatment" post="protocol.1 In addition to the potential ocular manifestations of"/>
 <result pre="to EKC, topical disinfection during active cases as well as" exact="treatment" post="of corneal sequelae using corticosteroids and immunosuppressive agents show"/>
 <result pre="nucleus, where viral replication occurs.2,7-9 Challenges HAdV causes a lytic" exact="infection" post="of the mucoepithelial cells of the conjunctiva and cornea"/>
 <result pre="of the conjunctiva and cornea as well as a latent" exact="infection" post="of lymphoid and adenoid cells.10 Members of Groups B"/>
 <result pre="facilitate dissemination of adenovirus into the community since subclinical adenoviral" exact="infection" post="of tonsillar and adenoid lymphoid tissue serve as a"/>
 <result pre="adenovirus in the stool of patients with previous adenoviral GIT" exact="infection" post="can also occur.3,11 Kosulin et al suggested that latent"/>
 <result pre="can also occur.3,11 Kosulin et al suggested that latent HAdV" exact="infection" post="of the gut lymphoid cell could serve as a"/>
 <result pre="shedding in stool.11,17,19-21 This is indicative of persistent subclinical HAdV" exact="infection" post="of the gut-associated lymphoid tissue.20 Immunocompetent individuals are likely"/>
 <result pre="also more likely to have reactivation of HAdV with productive" exact="infection" post="of intestinal epithelial cells and consequential extensive viral dissemination"/>
 <result pre="adenoviral shedding and its high propensity of spread via hand-to-eye" exact="contact" post="by those contaminated with fecal matter.18 Another significant challenge"/>
 <result pre="conjunctivitis via oculogenital contact. These cases highlight the importance of" exact="testing" post="for the presence of adenovirus in clinical specimens collected"/>
 <result pre="characteristics, ubiquity of HAdV, and its potential for epidemic, several" exact="treatment" post="modalities have been investigated to establish an effective treatment"/>
 <result pre="several treatment modalities have been investigated to establish an effective" exact="treatment" post="protocol. However, at this stage, there is no FDA-approved"/>
 <result pre="protocol. However, at this stage, there is no FDA-approved antiviral" exact="treatment" post="for HAdV infections. Povidone-Iodine Irrigation Though molecular iodine has"/>
 <result pre="established as an effective antiseptic agent, its formidable toxicity upon" exact="contact" post="to mucosal surfaces deterred it for use in clinical"/>
 <result pre="transmission of adenoviral keratoconjunctivitis. PVI has also shown value in" exact="treatment" post="formulations. A large clinical trial for the use of"/>
 <result pre="for the use of 1.25% PVI ophthalmic solution in the" exact="treatment" post="of pediatric conjunctivitis displayed efficacy in treatment of bacterial,"/>
 <result pre="solution in the treatment of pediatric conjunctivitis displayed efficacy in" exact="treatment" post="of bacterial, chlamydial, and viral conjunctivitis.40 Interestingly, a clinical"/>
 <result pre="artificial tears at pH 4.2 for enhanced tolerability) for the" exact="treatment" post="of adenoviral keratoconjunctivitis found faster recovery from disease at"/>
 <result pre="paved the way for its more focused evaluation for the" exact="treatment" post="of the ocular manifestations of this virus. Besides the"/>
 <result pre="gastroenteritis due to its propensity to infect mucosal epithelium.3,41,42 Respiratory" exact="infection" post="is typically mild and self-limiting in immunocompetent individuals, but"/>
 <result pre="self-limiting in immunocompetent individuals, but in rare cases, severe respiratory" exact="infection" post="and pneumonia may result in acute respiratory distress syndrome"/>
 <result pre="pediatric population.3 Despite thorough investigation on the role of antiviral" exact="treatment" post="both systemically and topically, there remains no standard of"/>
 <result pre="It was proposed that GCV inhibited the advancement of viral" exact="infection" post="into the late phase. Systemically, GCV was able to"/>
 <result pre="Systemically, GCV was able to mitigate the effects of HAdV" exact="infection" post="in these hamsters, decreasing the rate of mortality. This"/>
 <result pre="mortality. This led to the investigation of GCV in the" exact="treatment" post="of ocular infections of HAdV.43,44 The ophthalmic gel form"/>
 <result pre="Milan, Italy) has been the standard of care for the" exact="treatment" post="of acute ocular herpetic keratitis, yet it has not"/>
 <result pre="of drugs demonstrated a 91.76% cure rate in a 6-week" exact="treatment" post="period, with low risk of side effects limited to"/>
 <result pre="considered to be self-limiting, this study concluded that the proposed" exact="treatment" post="plan, specifically during the early phase of the disease,"/>
 <result pre="for valganciclovir, it would likely become a challenge in the" exact="treatment" post="of adenoviral keratoconjunctivitis.47 Ribavirin and cidofovir have also been"/>
 <result pre="an effective antiviral with a high therapeutic index for the" exact="treatment" post="of HAdV associated infections.46 In animal models, CDV was"/>
 <result pre="showed great promise in the future of cidofovir for the" exact="treatment" post="of ocular HAdV infections in the future.48 Additionally, early"/>
 <result pre="CDV in immunocompetent patients with HAdV pneumonia was an effective" exact="treatment" post="strategy.42 Due to the positive results in the aforementioned"/>
 <result pre="profile and poor bioavailability make CDV a less than ideal" exact="treatment" post="option for the treatment of HAdV associated infections, both"/>
 <result pre="make CDV a less than ideal treatment option for the" exact="treatment" post="of HAdV associated infections, both systemically and locally. The"/>
 <result pre="Averbuch et al. reported successful use of BCV in the" exact="treatment" post="of adenoviral infection in a patient with primary immunodeficiency"/>
 <result pre="reported successful use of BCV in the treatment of adenoviral" exact="infection" post="in a patient with primary immunodeficiency whereas Florescu et"/>
 <result pre="al demonstrated that it was clinically beneficial in treating adenoviral" exact="infection" post="in immunocompromised individuals who were at risk of disseminated"/>
 <result pre="of BCV systemically, as well as its potential for the" exact="treatment" post="of adenoviral ocular infections. Clinical development of this drug"/>
 <result pre="the antibodies' ability to target adenoviral capsid proteins, subsequently inhibiting" exact="infection" post="by the virus.58 Topically, immunoglobulin (Ig) may offer the"/>
 <result pre="scarring or corneal neovascularization formation.2,12,62 Research demonstrates that mild corticosteroid" exact="treatment" post="administered topically approximately three times per day can significantly"/>
 <result pre="use of topical corticosteroids once the acute phase of the" exact="infection" post="resolves, for the remaining, persistent SEIs.2,63 While chronic corticosteroid"/>
 <result pre="infection resolves, for the remaining, persistent SEIs.2,63 While chronic corticosteroid" exact="treatment" post="has been proven to reduce these findings, a significant"/>
 <result pre="reduce these findings, a significant challenge to this mode of" exact="treatment" post="is the risk of complications of long-term use, including"/>
 <result pre="of long-term use, including glaucoma and cataract formation.64â€“69 Additionally, corticosteroid" exact="treatment" post="of SEIs can result in a 17.5% recurrence rate"/>
 <result pre="study comparing topical loteprednol with dexamethasone, similar outcomes in SEI" exact="treatment" post="were observed. This is significant because milder topical steroid"/>
 <result pre="adverse effects.71 However, it is important to note that short-term" exact="treatment" post="with topical steroids of limited potency may also delay"/>
 <result pre="it affect the duration of viral shedding. In contrast, prednisolone" exact="treatment" post="was shown to prolong viral shedding.73 As it pertained"/>
 <result pre="to prolong viral shedding.73 As it pertained to sub-epithelial infiltrates," exact="treatment" post="with diclofenac or ketorolac did not yield a statistically"/>
 <result pre="risk of developing corneal findings as well as the chronic" exact="treatment" post="of persistent SEIs, with most cases resolving over a"/>
 <result pre="USA) once per day or once every other day, in" exact="treatment" post="of SEIs secondary to adenoviral epidemic keratoconjunctivitis in cases"/>
 <result pre="limbic keratoconjunctivitis, and many others.69,79-81 Asena et al also evaluated" exact="treatment" post="options for acute adenoviral keratoconjunctivitis using either topical 1%"/>
 <result pre="cells.70,84-86 Topical tacrolimus 0.03% has ophthalmic uses, mainly in the" exact="treatment" post="of giant papillary conjunctivitis and vernal keratoconjunctivitis. With regards"/>
 <result pre="was proven to be an effective corticosteroid-sparing agent.87 Another promising" exact="treatment" post="for HAdV is adoptive T cell therapy. This involves"/>
 <result pre="be efficacious against HAdV serotypes A-D and serve as potential" exact="treatment" post="therapies for the treatment and prophylaxis of EKC.88 Thus,"/>
 <result pre="serotypes A-D and serve as potential treatment therapies for the" exact="treatment" post="and prophylaxis of EKC.88 Thus, repurposing of these cardiotonic"/>
 <result pre="of these cardiotonic steroids as an antiviral agent for short-term" exact="treatment" post="of adenoviral keratoconjunctivitis as well as a prophylactic for"/>
 <result pre="well as a prophylactic for use in individuals in close" exact="contact" post="with patients with epidemic keratoconjunctivitis.88 Furthermore, Marrugal-Lorenzo et al"/>
 <result pre="inflammation, with the added benefit of reducing the risk and/or" exact="treatment" post="of SEI formation and scarring.2,52,72,91 Initial efficacy of combo"/>
 <result pre="as determined by cell culture with confirmatory immunofluorescence) endpoints.91 Combination" exact="treatment" post="dosed QID for seven days has also been shown"/>
 <result pre="friability of vasculature, inflammatory discharge, and epiphora as compared to" exact="treatment" post="with 0.5% cidofovir, tobramycin/dexamethasone ophthalmic suspension, and balanced salt"/>
 <result pre="viral titers and delaying viral shedding.52 When comparing PVI/dexamethasone combination" exact="treatment" post="with that of dexamethasone alone, combination drops not only"/>
 <result pre="shedding, further delaying the resolution of active infection. This significant" exact="treatment" post="challenge is alleviated with the addition of PVI.92 In"/>
 <result pre="with the addition of PVI.92 In addition to the mentioned" exact="treatment" post="benefits, combination PVI/dexamethasone ophthalmic formulation displayed a favorable safety"/>
 <result pre="were limited to increased stinging upon instillation when compared to" exact="treatment" post="with palliative artificial tears.94 Surgical Management Surgical management is"/>
 <result pre="high contagion risk, and potential long-term visual complications require a" exact="treatment" post="protocol. Studies have indicated that the inflammatory process affecting"/>
 <result pre="of human ocular anatomy while also illustrating proper replication and" exact="infection" post="of human adenoviruses can prove decelerating for new discovery.95Table"/>
 <result pre="this review.2,46,55,63,64,66,69,87,104-124 In summary, there are several challenges regarding the" exact="treatment" post="of adenoviral keratoconjunctivitis. Though there are solutions to some"/>
 <result pre="efficacious against HAdV types that cause EKC.46 Ganciclovir ophthalmic gel" exact="treatment" post="prevents complications in adenoviral ocular infection. 109 Transient blur"/>
 <result pre="symptomology and SEIs70 as well as a safe and effective" exact="treatment" post="of adenoviral SEIs.87,122,123 Transient burning sensation.124 Table 3 Challenges"/>
 <result pre="of persistent latent HAdV in the host Prevention of spread," exact="treatment" post="of immunocompromised individuals Group D HAdV can cause oculogenital"/>
 <result pre="treatment of immunocompromised individuals Group D HAdV can cause oculogenital" exact="infection" post="Appropriate testing for HAdV subtype from urethra and conjunctiva"/>
 <result pre="immunocompromised individuals Group D HAdV can cause oculogenital infection Appropriate" exact="testing" post="for HAdV subtype from urethra and conjunctiva in men"/>
 <result pre="Virol. 1981;7(2):105â€“118. doi:10.1002/jmv.18900702047264611 27.SunG, SuG, BaiY, YangH. Analysis on the" exact="treatment" post="and prevention of epidemic conjunctivitis in 108 cases. Pak"/>
 <result pre="Pharmacother. 2015;16(14):2095â€“2099. doi:10.1517/14656566.2015.108397526330121 45.BrunoB, GooleyT, HackmanRC, DavisC, CoreyL, BoeckhM. Adenovirus" exact="infection" post="in hematopoietic stem cell transplantation: effect of ganciclovir and"/>
 <result pre="TrousdaleMD. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5" exact="infection" post="in vitro and in a New Zealand rabbit ocular"/>
 <result pre="Transplant. 2017;23(3):512â€“521. doi:10.1016/j.bbmt.2016.12.62128063938 56.AverbuchD, SafadiR, DarD, et al. Successful brincidofovir" exact="treatment" post="of metagenomics-detected adenovirus infection in a severely ill signal"/>
 <result pre="SafadiR, DarD, et al. Successful brincidofovir treatment of metagenomics-detected adenovirus" exact="infection" post="in a severely ill signal transducer and activator of"/>
 <result pre="1% with and without cyclosporin a 1% as a topical" exact="treatment" post="of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study."/>
 <result pre="study. Ophthalmology. 2002;109(5):845â€“850. doi:10.1016/S0161-6420(02)00992-211986086 65.HillenkampJ, ReinhardT, RossRS, et al. Topical" exact="treatment" post="of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1%"/>
 <result pre="Arch Ophthalmol. 2001;119(10):1487â€“1491. doi:10.1001/archopht.119.10.148711594949 66.LevingerE, SlomovicA, SansanayudhW, BaharI, SlomovicAR. Topical" exact="treatment" post="with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral"/>
 <result pre="Topical 2% cyclosporine A in preservative-free artificial tears for the" exact="treatment" post="of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41(6):693â€“698. doi:10.3129/i06-06117224949 69.OkumusS,"/>
 <result pre="TatarMG, et al. Cyclosporine a 0.05% eye drops for the" exact="treatment" post="of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol. 2012;12:42."/>
 <result pre="Indian J Ophthalmol. 2019;67(5):594â€“598. doi:10.4103/ijo.IJO_1352_1831007215 71.KoclukY, SukgenEA, CevherS, MatE. Symptomatic" exact="treatment" post="of subepithelial infiltrates after viral conjunctivitis: loteprednol or dexamethasone?Ocul"/>
 <result pre="BurcuA, ErcanE, ColakM, AltinorsDD. Comparison of clinical outcome with different" exact="treatment" post="regimens in acute adenoviral keratoconjunctivitis. Eye (Lond). 2017;31(5):781â€“787. doi:10.1038/eye.2017.428157224"/>
 <result pre="80.HollandEJ, OlsenTW, KetchamJM, et al. Topical cyclosporin A in the" exact="treatment" post="of anterior segment inflammatory disease. Cornea. 1993;12(5):413â€“419. doi:10.1097/00003226-199309000-000088306663 81.PerryHD,"/>
 <result pre="DonnenfeldED, KornsteinHS. Topical cyclosporine A 0.5% as a possible new" exact="treatment" post="for superior limbic keratoconjunctivitis. Ophthalmology. 2003;110(8):1578â€“1581. doi:10.1016/S0161-6420(03)00538-412917176 82.FahrA. Cyclosporin"/>
 <result pre="Dial Transplant. 2000;15(12):1916â€“1918. doi:10.1093/ndt/15.12.191611096132 87.GhanemRC, VargasJF, GhanemVC. Tacrolimus for the" exact="treatment" post="of subepithelial infiltrates resistant to topical steroids after adenoviral"/>
 <result pre="KnightA. Ionic Contra-Viral Therapy (ICVT); a new approach to the" exact="treatment" post="of DNA virus infections. Arch Virol. 2006;151(12):2495â€“2501. doi:10.1007/s00705-006-0824-x16932984 90.Marrugal-lorenzoJA,"/>
 <result pre="2006;151(12):2495â€“2501. doi:10.1007/s00705-006-0824-x16932984 90.Marrugal-lorenzoJA, Serna-gallegoA, Gonzalez-gonzalezL, et al. Inhibition of adenovirus" exact="infection" post="by mifepristone. Antiviral Res. 2018;159:77â€“83. doi:10.1016/j.antiviral.2018.09.01130268911 91.PelletierJS, StewartK, TrattlerW,"/>
 <result pre="al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the" exact="treatment" post="of adenoviral conjunctivitis. Adv Ther. 2009;26(8):776â€“783. doi:10.1007/s12325-009-0062-119756415 92.KovalyukN, KaisermanI,"/>
 <result pre="AbeRY, et al. Dexamethasone/povidone eye drops versus artificial tears for" exact="treatment" post="of presumed viral conjunctivitis: a randomized clinical trial. Curr"/>
 <result pre="doi:10.1016/j.jcv.2019.01.00430654207 96.YamazakiES, FerrazCA, HazarbassanovRM, AllemannN, CamposM. Phototherapeutic keratectomy for the" exact="treatment" post="of corneal opacities after epidemic keratoconjunctivitis. Am J Ophthalmol."/>
 <result pre="TothK. Cidofovir and brincidofovir reduce the pathology caused by systemic" exact="infection" post="with human type 5 adenovirus in immunosuppressed Syrian hamsters,"/>
 <result pre="YabikuMM, BottosKM, AraujoAL, FreitasD, BelfortRJr.[Ganciclovir 0.15% ophthalmic gel in the" exact="treatment" post="of adenovirus keratoconjunctivitis]. Arq Bras Oftalmol. 2011;74(6):417â€“421. Portuguese. doi:10.1590/S0004-27492011000600007.22331114"/>
 <result pre="Bras Oftalmol. 2011;74(6):417â€“421. Portuguese. doi:10.1590/S0004-27492011000600007.22331114 109.OzenS, OzerMA. Ganciclovir ophthalmic gel" exact="treatment" post="shortens the recovery time and prevents complications in the"/>
 <result pre="Dis. 2005;191(3):396â€“399. doi:10.1086/jid.2005.191.issue-315633099 111.Van GenechtenT, van HeerdenJ, BautersT, DhoogeC. Successful" exact="treatment" post="of adenovirus infection with brincidofovir in an immunocompromised patient"/>
 <result pre="111.Van GenechtenT, van HeerdenJ, BautersT, DhoogeC. Successful treatment of adenovirus" exact="infection" post="with brincidofovir in an immunocompromised patient after hematological stem"/>
 <result pre="safety profile of brincidofovir: a favorable benefit-risk proposition in the" exact="treatment" post="of smallpox. Antiviral Res. 2017;143:269â€“277. doi:10.1016/j.antiviral.2017.01.00928093339 115.MartyFM, WinstonDJ, ChemalyRF,"/>
 <result pre="doi:10.1111/ajd.2015.56.issue-325754554 117.JengBH, HolsclawDS. Cyclosporine A 1% eye drops for the" exact="treatment" post="of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30(9):958â€“961. doi:10.1097/ICO.0b013e31820cd60721673568"/>
 <result pre="118.MuftuogluIK, AkovaYA, GungorSG. Effect of 0.05% topical cyclosporine for the" exact="treatment" post="of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis. Int"/>
 <result pre="of two different topical 0.05% cyclosporine a formulations in the" exact="treatment" post="of adenoviral keratoconjunctivitis-related subepithelial infiltrates. Case Rep Ophthalmol. 2016;7(1):135â€“140."/>
 <result pre="2010;23(3):865â€“871. doi:10.1177/03946320100230032220943058 121.SchultzC. Safety and efficacy of cyclosporine in the" exact="treatment" post="of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37â€“42. doi:10.4137/OED.S1606725002818"/>
</results>
